A phase I study of KB004 for the treatment of solid tumours
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Ifabotuzumab (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 07 Aug 2017 According to Humanigen media release, KaloBios Pharmaceuticals changed its name to Humanigen.
- 19 Oct 2015 New trial record
- 15 Oct 2015 According to a company media release, KaloBios plans to initiate this study in early 2016.